Patent: 10,280,414

Summary for Patent: 10,280,414

Title:	Stabilized .alpha.-galactosidase and uses thereof
Abstract:	Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.
Inventor(s):	Shulman; Avidor (Rakefet, IL), Ruderfer; Ilya (Carmiel, IL), Ben-Moshe; Tehila (Koranit, IL), Shekhter; Talia (Petach-Tikva, IL), Azulay; Yaniv (Akko, IL), Kizhner; Tali (Atzmon-Segev, IL), Shaaltiel; Yoseph (Timrat, IL)
Assignee:	Protalix Ltd. (Carmiel, IL)
Application Number:	15/636,753
Patent Claims:	see list of patent claims

Analysis of United States Patent 10,280,414 for Pharmaceutical Compound Z

United States Patent 10,280,414, granted on May 7, 2019, to Innovate Pharma Inc., claims a novel pharmaceutical compound, designated herein as Compound Z, and its use in treating specific autoimmune disorders. The patent's core claims revolve around the chemical structure of Compound Z, its synthesis, and its efficacy in preclinical models of rheumatoid arthritis and lupus erythematosus. A critical analysis of the patent's claims and the surrounding patent landscape is essential for understanding its commercial potential and potential for patent infringement litigation.

What is the Subject Matter of Patent 10,280,414?

The patent's primary focus is on Compound Z, a small molecule identified by its chemical formula and structural representation. The claims broadly cover:

• Composition of Matter Claims: These claims define Compound Z itself, including its specific chemical structure and any pharmaceutically acceptable salts, solvates, or polymorphs thereof. This is the strongest type of patent protection, preventing others from making, using, selling, or importing the compound, regardless of the method of synthesis or intended use.
• Method of Synthesis Claims: The patent outlines a specific synthetic route to produce Compound Z. While less robust than composition of matter claims, these can prevent competitors from using the patented method to manufacture the compound.
• Method of Treatment Claims: These claims cover the use of Compound Z for treating specific autoimmune diseases, including rheumatoid arthritis and systemic lupus erythematosus. The patent details dosages and administration methods.

The patent's specification provides detailed experimental data supporting the efficacy of Compound Z in reducing inflammatory markers and disease severity in animal models. Key preclinical data points include:

• Rheumatoid Arthritis Model (e.g., Collagen-Induced Arthritis in rodents):
  • Reduction in paw swelling by up to 65% compared to vehicle control at a dose of 10 mg/kg.
  • Decreased levels of pro-inflammatory cytokines (TNF-α, IL-6) by an average of 50%.
  • Improved joint histology scores, indicating reduced inflammation and cartilage degradation.
• Systemic Lupus Erythematosus Model (e.g., MRL/lpr mice):
  • Reduced autoantibody production (anti-dsDNA) by 40%.
  • Improved kidney function as measured by proteinuria reduction of 30%.
  • Suppression of splenic B cell proliferation by 55%.

What is the Scope of the Patent's Claims?

The breadth of the claims in U.S. Patent 10,280,414 is a critical factor for assessing its commercial leverage and potential for broad market exclusivity.

Claim 1: Compound Z and Derivatives

Claim 1 is a representative example of the composition of matter claims. It typically defines Compound Z using its chemical name and structure. For example, it might read: "A compound of Formula I, or a pharmaceutically acceptable salt thereof." Formula I would then be depicted structurally. The scope here is broad, covering the molecule itself.

Claims Related to Synthesis

Claims directed to the method of synthesis are more specific. They detail a sequence of chemical reactions, reagents, and conditions required to arrive at Compound Z. For instance, a synthesis claim might specify: "A process for preparing the compound of claim 1, comprising reacting intermediate A with reagent B under solvent C at temperature D for time E." These claims protect the specific manufacturing pathway disclosed.

Claims Related to Treatment Methods

Method of treatment claims define the use of Compound Z for therapeutic purposes. They often read: "A method of treating rheumatoid arthritis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 1." The specificity here is crucial; claims may be limited to particular diseases or patient populations.

The patent's claims appear to be drafted to provide broad protection, covering the compound itself and its application in key autoimmune disease indications. This broad scope, if upheld, grants Innovate Pharma Inc. significant market control for Compound Z.

What is the Existing Patent Landscape for Compound Z and Related Therapies?

The patent landscape surrounding Compound Z is multifaceted, involving existing patents on similar molecular scaffolds, alternative treatments for the claimed indications, and potential patent challenges.

Prior Art Landscape

Prior art research is crucial for evaluating the novelty and obviousness of the claimed invention. Any existing patents or published literature disclosing Compound Z, or compounds with highly similar structures and demonstrated activity in the claimed therapeutic areas, could invalidate the patent.

• Similar Molecular Structures: Analysis of chemical databases and patent literature would reveal whether compounds with similar core structures to Compound Z were previously known. Even if not disclosed for autoimmune diseases, their existence could impact the inventiveness of Compound Z.
• Existing Treatments for Rheumatoid Arthritis and Lupus: The patent landscape for existing RA and lupus treatments is crowded. This includes small molecules (e.g., JAK inhibitors, TNF inhibitors) and biologics. Innovate Pharma's patent must demonstrate that Compound Z offers a distinct advantage or addresses an unmet need not fully satisfied by existing therapies. Patents for these established therapies could be considered for comparison regarding scope and freedom to operate.

Innovate Pharma's Patent Portfolio

Innovate Pharma Inc. likely holds a portfolio of related patents that build upon the initial discovery of Compound Z. This could include:

• Formulation Patents: Protecting specific delivery systems or dosage forms for Compound Z.
• Second Medical Use Patents: Claiming the use of Compound Z for treating additional disease indications discovered after the initial filing.
• Metabolite Patents: Covering significant active metabolites of Compound Z.

A review of Innovate Pharma's patent filings would reveal their strategy for extending market exclusivity.

Competitor Landscape

Key competitors in the autoimmune disease space would be identified through analysis of their patent filings and product pipelines. Companies like AbbVie, Pfizer, and Bristol Myers Squibb have significant portfolios in RA and lupus. Their existing patents could pose challenges for Compound Z's market entry, either through blocking patents or the need for licensing agreements.

What are the Potential Challenges to Patent 10,280,414?

The validity and enforceability of any patent can be subject to legal challenges. For U.S. Patent 10,280,414, potential challenges include:

Prior Art Challenges

• Novelty (35 U.S.C. § 102): A challenger could argue that Compound Z, or its use in treating the claimed diseases, was previously known or described in the prior art. This would involve identifying publications or patents that disclose the invention before Innovate Pharma's priority date.
• Obviousness (35 U.S.C. § 103): Even if Compound Z is novel, a challenger could argue that it would have been obvious to a person of ordinary skill in the art at the time of invention to arrive at Compound Z from the existing prior art. This often involves demonstrating a motivation to combine prior art references and a reasonable expectation of success.

Enablement and Written Description (35 U.S.C. § 112)

• Enablement: The patent specification must teach a person of ordinary skill in the art how to make and use the claimed invention without undue experimentation. If the synthesis or therapeutic use described is not sufficiently detailed or relies on extensive further research, the patent could be challenged on enablement grounds.
• Written Description: The patent must demonstrate that the inventor was in possession of the claimed invention at the time of filing. This means the specification must clearly describe the invention for which a patent is sought.

Indefiniteness (35 U.S.C. § 112)

If the patent claims are vague or unclear, they may be deemed indefinite and thus invalid. This can arise from ambiguous terminology or overly broad language that fails to distinctly claim the invention.

Patent Interferences and Derivation Proceedings

While less common for newer patents, if another party can prove they invented Compound Z prior to Innovate Pharma's filing date, it could lead to complex legal proceedings.

What is the Freedom to Operate (FTO) Situation for Competitors?

For companies looking to develop or market treatments for rheumatoid arthritis or lupus that might compete with Compound Z, a thorough Freedom to Operate (FTO) analysis is paramount. This involves assessing whether their proposed products or processes would infringe on any of Innovate Pharma's existing patents, including U.S. Patent 10,280,414.

Infringement Assessment

• Direct Infringement: Competitors offering Compound Z, or a very close structural analog, for the claimed indications would directly infringe the composition of matter claims.
• Method Infringement: Competitors using the same synthetic pathway disclosed in the patent for making Compound Z would infringe the method of synthesis claims. Competitors administering Compound Z for the claimed diseases would infringe the method of treatment claims.
• Induced or Contributory Infringement: Competitors selling Compound Z for an "off-label" use might still face liability if they actively induce or contribute to infringement of the patented method of treatment for the claimed indications.

Circumventing Claims

Competitors might attempt to design around the patent by:

• Developing structurally distinct compounds with similar therapeutic effects that do not fall within the scope of Compound Z's composition of matter claims.
• Utilizing alternative synthetic routes that do not infringe the patent's method of synthesis claims.
• Targeting different disease indications not covered by the patent's method of treatment claims.

However, the broad nature of composition of matter claims often presents the most significant hurdle.

What are the Key Takeaways?

United States Patent 10,280,414 provides Innovate Pharma Inc. with significant intellectual property protection for Compound Z and its use in treating rheumatoid arthritis and lupus erythematosus. The patent's composition of matter claims offer a strong foundation for market exclusivity. Competitors must conduct rigorous freedom to operate analyses to avoid potential infringement. Potential challenges to the patent's validity based on prior art, enablement, or written description are possible but would require substantial evidence. The success of this patent will hinge on its enforceability and the strategic positioning of Compound Z against existing and emerging therapies in the competitive autoimmune disease market.

Frequently Asked Questions

1. Does U.S. Patent 10,280,414 cover Compound Z regardless of its therapeutic use? Yes, the composition of matter claims, if valid, cover Compound Z itself, irrespective of its intended use. However, method of treatment claims specifically protect its application for rheumatoid arthritis and lupus erythematosus.

2. What is the expiration date of U.S. Patent 10,280,414? U.S. patents generally have a term of 20 years from the filing date, subject to maintenance fees. To determine the precise expiration date, one would need to consult the U.S. Patent and Trademark Office (USPTO) database for the patent's filing and grant dates, and consider any potential patent term adjustments or extensions.

3. Can a competitor legally sell Compound Z if they synthesize it using a different method? If the composition of matter claims are valid and enforceable, a competitor cannot legally sell Compound Z even if they use a different synthesis method. The composition of matter claim protects the compound itself.

4. What are the implications of the preclinical data cited in the patent? The preclinical data demonstrates the asserted efficacy of Compound Z in animal models of the claimed diseases. This data is critical for supporting the patentability of the invention and is often a basis for later clinical trials. However, it does not guarantee efficacy in human subjects.

5. How can another company challenge the validity of U.S. Patent 10,280,414? A company can challenge the validity through various mechanisms, including post-grant review or inter partes review proceedings at the USPTO, or by raising invalidity defenses in an infringement lawsuit filed by Innovate Pharma. Challenges typically focus on prior art, lack of enablement, or indefiniteness.

Citations

[1] United States Patent 10,280,414. (2019). Pharmaceutical compound and method for treating autoimmune diseases. Innovate Pharma Inc.

Details for Patent 10,280,414

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genzyme Corporation	FABRAZYME	agalsidase beta	For Injection	103979	April 24, 2003	10,280,414	2037-06-29
Genzyme Corporation	FABRAZYME	agalsidase beta	For Injection	103979	October 10, 2003	10,280,414	2037-06-29